176 related articles for article (PubMed ID: 30698790)
1. Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations.
Parilla M; Kadri S; Patil SA; Fitzpatrick C; Ritterhouse L; Segal J; Collins J; Pytel P
J Neuropathol Exp Neurol; 2019 Mar; 78(3):257-267. PubMed ID: 30698790
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
[TBL] [Abstract][Full Text] [Related]
3. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
4. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors.
Carter JH; McNulty SN; Cimino PJ; Cottrell CE; Heusel JW; Vigh-Conrad KA; Duncavage EJ
J Mol Diagn; 2017 Mar; 19(2):328-337. PubMed ID: 28042970
[TBL] [Abstract][Full Text] [Related]
5. [Classification of gliomas. Current progress and perspectives].
Capper D; Reifenberger G
Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.
Lorenz J; Rothhammer-Hampl T; Zoubaa S; Bumes E; Pukrop T; Kölbl O; Corbacioglu S; Schmidt NO; Proescholdt M; Hau P; Riemenschneider MJ
Acta Neuropathol Commun; 2020 Aug; 8(1):124. PubMed ID: 32758285
[TBL] [Abstract][Full Text] [Related]
7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.
Sahm F; Schrimpf D; Jones DT; Meyer J; Kratz A; Reuss D; Capper D; Koelsche C; Korshunov A; Wiestler B; Buchhalter I; Milde T; Selt F; Sturm D; Kool M; Hummel M; Bewerunge-Hudler M; Mawrin C; Schüller U; Jungk C; Wick A; Witt O; Platten M; Herold-Mende C; Unterberg A; Pfister SM; Wick W; von Deimling A
Acta Neuropathol; 2016 Jun; 131(6):903-10. PubMed ID: 26671409
[TBL] [Abstract][Full Text] [Related]
10. Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.
Arcella A; Limanaqi F; Ferese R; Biagioni F; Oliva MA; Storto M; Fanelli M; Gambardella S; Fornai F
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31968687
[TBL] [Abstract][Full Text] [Related]
11. Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.
Shin H; Sa JK; Bae JS; Koo H; Jin S; Cho HJ; Choi SW; Kyoung JM; Kim JY; Seo YJ; Joung JG; Kim NKD; Son DS; Chung J; Lee T; Kong DS; Choi JW; Seol HJ; Lee JI; Suh YL; Park WY; Nam DH
Cancer Res Treat; 2020 Jan; 52(1):41-50. PubMed ID: 31096737
[TBL] [Abstract][Full Text] [Related]
12. Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing.
Lenting K; van den Heuvel CNAM; van Ewijk A; ElMelik D; de Boer R; Tindall E; Wei G; Kusters B; Te Dorsthorst M; Ter Laan M; Huynen MA; Leenders WP
Acta Neuropathol Commun; 2019 Nov; 7(1):185. PubMed ID: 31747973
[TBL] [Abstract][Full Text] [Related]
13. Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?
Kam KL; Appin CL; Mao Q; Ikegami S; Lukas RV; Nikiforova MN; Roy S; Brat DJ; Horbinski C
J Neuropathol Exp Neurol; 2020 Jul; 79(7):763-766. PubMed ID: 32483596
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
15. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
16. Progress on molecular biomarkers and classification of malignant gliomas.
Zhang C; Bao Z; Zhang W; Jiang T
Front Med; 2013 Jun; 7(2):150-6. PubMed ID: 23681890
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of gliomas.
Masui K; Mischel PS; Reifenberger G
Handb Clin Neurol; 2016; 134():97-120. PubMed ID: 26948350
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of adult gliomas: recent advances and future perspectives.
Barritault M; Meyronet D; Ducray F
Curr Opin Oncol; 2018 Nov; 30(6):375-382. PubMed ID: 30148717
[TBL] [Abstract][Full Text] [Related]
19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
20. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
